SJP-001

SJP-001 is a novel, investigational combination drug developed for the prevention and treatment of alcohol-induced hangover. It consists of two active pharmaceutical ingredients: naproxen (a nonsteroidal anti-inflammatory drug, NSAID) and fexofenadine (an H1-antagonist antihistamine). The primary mechanism of action is to reduce the inflammatory response triggered by alcohol consumption, which is believed to be a key driver of hangover symptoms such as headache, nausea, dizziness, thirst, tiredness, and loss of appetite. Preclinical studies and early clinical trials have shown that SJP-001 can significantly reduce overall hangover severity compared to placebo. The product is being positioned as potentially the first FDA-approved therapy specifically for hangover prevention and may be available both over-the-counter and by prescription if approved[2][3][4][5][7].

Brand names

SJP-001SJP001SJP 001

Other names

naproxen + fexofenadine